Thompson Elizabeth H.Z.
Known title: EVP, Head of Research & DevCIK: 0001861477
Associated companies
Transaction History
| ACAD | ▼ Sell | Open Market | 16,508 | $431K | 7/30/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 50 | $1K | 7/30/2026 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 32,272 | — | 7/29/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 3,435 | $74K | 3/25/2026 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 6,715 | — | 3/24/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates
RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates. RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.